Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine for superficial bladder cancer
NCT00191477Phase 3Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2004
- Primary completion
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in transitional cell carcinoma of the bladder (TCC) comparing Gemcitabine with Placebo (2 arms). Primary endpoint: Recurrence-Free Survival at 24 months. Started Jan 2004; status: terminated.
02
Drugs
gemcitabine
03
Conditions
transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on NCT00191477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00191477.